Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Assess prices and public offering value. Keep track of the latest IPO stocks, news and Initial Public Offering (IPO) analysis. Filter upcoming IPOs by country (UK IPOs, US IPOs, etc), listing date, ...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform ...

REDWOOD CITY, Calif. & BOSTON, January 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...

The oil and natural gas producer, backed by private equity firms Pearl Energy Investments and NGP, priced its IPO at $20 per share, within the expected range of $18 to $21. The stock opened at $22 ...

has priced its initial public offering or IPO of 8.8 million shares of common stock at $16.00 each, raising gross proceeds of $140 million. The shares would debut on the Nasdaq Global Market on ...

A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...

Shares of INMB opened at $9.22 on Tuesday. The company has a 50-day moving average price of $5.62 and a two-hundred day moving average price of $6.08. The stock has a market cap of $204.43 million ...

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on ...

Nasdaq maintained its leadership in listings, with 180 IPOs in 2024, raising $23 billion in total proceeds, and achieved an 80% win rate among eligible operating company IPOs in the US.